Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Livio, Puglia"'
Autor:
Ferdinando Riccardi, Bruno Chiurazzi, Raffaella Ruocco, Francesca Ambrosio, Maria Fiorella Brangi, Carmela Barbato, Vincenzo Di Lauro, Dario Arundine, M. Biglietto, Roberto Fiorentino, Francesco Jacopo Romano, Maresa Cammarota, Sarah Scagliarini, Livio Puglia, Ivana Cerillo, Carmen Mocerino
Publikováno v:
Oncotarget
The stock of therapeutic weapons available in metastatic colorectal cancer (mCRC) has been progressively grown over the years, with improving both survival and patients' clinical outcome: notwithstanding advances in the knowledge of mCRC biology, as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8b5a171e52b2a89d9e884a1160d08dc
https://doi.org/10.18632/oncotarget.27872
https://doi.org/10.18632/oncotarget.27872
Autor:
Michele Aieta, Ilaria Ascione, Sabino De Placido, Livio Puglia, Gaetano Facchini, Michele Caraglia, Carlo Buonerba, Matteo Ferro, Guru Sonpavde, Davide Bosso, Giuseppe Di Lorenzo, Giuseppe Lucarelli, Martina Pagliuca, Daniela Terracciano, Sabrina Rossetti, Ottavio De Cobelli, Piero Pignataro
Publikováno v:
Expert Opinion on Biological Therapy. 16:1387-1401
Introduction: While the majority of the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors currently used for the therapy of metastatic renal cell carcinoma (mRCC) are small molecule agents inhibiting multip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c5ac616be9e3787c9472d560879f2c
https://doi.org/10.1080/14712598.2016.1216964
https://doi.org/10.1080/14712598.2016.1216964
Autor:
Piera Federico, Sabino De Placido, Giovannella Palmieri, Guru Sonpavde, Livio Puglia, Carla Cavaliere, Carlo Buonerba, Giuseppe Di Lorenzo, Pasquale Rescigno, Matteo Ferro, Carmine D'Aniello, Davide Bosso
Publikováno v:
Anti-Cancer Drugs. 24:84-89
To determine the impact of prophylaxis with granulocyte-colony stimulating growth factor (G-CSF) on the risk of febrile neutropenia in a cohort of patients enrolled at the University Federico II of Naples and treated with cabazitaxel for metastatic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b80ed9989e09108c24b32ac30004f59
https://doi.org/10.1097/cad.0b013e32835a56bc
https://doi.org/10.1097/cad.0b013e32835a56bc
Autor:
Brigitta Mucci, Livio Puglia, Sabino De Placido, Guru Sonpavde, Francesca Foschini, Carlo Buonerba, Simona Iaccarino, Ileana Di Costanzo, Giuseppe Di Lorenzo, Francesca Vitrone, Vincenzo Tortora, Vittorio Riccio, Luca Scafuri, Margherita Muratore, Dario Ribera, Davide Bosso, Mirta Mosca, Martina Pagliuca, Nicola Cesarano, Michela Izzo, Rocco Morra
Publikováno v:
Journal of Cancer
Background: Cabazitaxel is a second-generation taxane that is approved for use with concomitant low dose daily prednisone in metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. Since the role of daily corticosteroids in i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1bf287bdf1551393db0df7f27ce1add
http://hdl.handle.net/11588/789593
http://hdl.handle.net/11588/789593
Autor:
Angela Gernone, Davide Dondi, Guru Sonpavde, Sergio Bracarda, Caterina Messina, Giuseppe Lucarelli, Giuseppe Di Lorenzo, Vittorina Zagonel, Davide Bosso, Donatello Gasparro, Livio Puglia, Carlo Buonerba, Sabino De Placido
Publikováno v:
Medicine
Cabazitaxel provided a survival advantage compared with mitoxantrone in patients with castration-resistant prostate cancer refractory to docetaxel. Grade 3 to 4 (G3–4) neutropenia and febrile neutropenia were relatively frequent in the registrative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de607b89807091e1ca82dc597a15b620
http://hdl.handle.net/11588/624380
http://hdl.handle.net/11588/624380
Autor:
Guru Sonpavde, Alfredo Marinelli, Sabino De Placido, Livio Puglia, Matteo Ferro, Michele Aieta, Pasquale Rescigno, Giovannella Palmieri, Carmine D'Aniello, Piera Federico, Antonella Petremolo, Giuseppe Di Lorenzo, Vincenzo Mirone, Carlo Buonerba, Sisto Perdonà
Publikováno v:
BJU International. 110:E661-E666
UNLABELLED What's known on the subject? and What does the study add? Metastatic or locally advanced squamous cell carcinoma of the penis (SCCP) is generally incurable, but it can be palliated with systemic chemotherapy. Two retrospective studies, inv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3d152f7cfafad7e8f84f57d8165d51
https://doi.org/10.1111/j.1464-410x.2012.11453.x
https://doi.org/10.1111/j.1464-410x.2012.11453.x
Autor:
Livio Puglia, Giuseppe Di Lorenzo, Giovannella Palmieri, Lucia Nappi, Pasquale Rescigno, Elide Matano, Vincenzo Damiano, Carmine D'Aniello, Piera Federico, Antonella Petremolo, Lucia Raimondo
Publikováno v:
Open Journal of Urology. :83-86
Primary germ cell tumors of lung are extremely rare. The prognosis is usually poor, with various symptoms seriously affecting quality of life. In this paper we describe the unique case of a patient affected by an embryonal carcinoma of lung and a tes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45bc342f1056de2cd5036d6fa0285c45
https://doi.org/10.4236/oju.2012.22016
https://doi.org/10.4236/oju.2012.22016
Autor:
Piera Federico, Carla Cavaliere, Carmine D'Aniello, Giuseppe Di Lorenzo, Livio Puglia, Sabino De Placido, Sisto Perdonà, Pasquale Rescigno, Matteo Ferro, Carlo Buonerba, Vincenzo Altieri
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2011, 67 (6), pp.1455-1461. ⟨10.1007/s00280-011-1594-z⟩
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2011, 67 (6), pp.1455-1461. ⟨10.1007/s00280-011-1594-z⟩
Docetaxel represents the first-line treatment for castration-resistant prostate cancer (CRPC). New therapeutic options are needed for subsequent lines of therapy in CRPC patients. Patients with progressive CRPC, pretreated with docetaxel, were enroll
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::713386520ed506e54a3489226f341239
https://doi.org/10.1007/s00280-011-1594-z
https://doi.org/10.1007/s00280-011-1594-z
Autor:
Sabino De Placido, Gregory R. Pond, Michele Aieta, Guru Sonpavde, Sisto Perdonà, Giuseppe Di Lorenzo, Carlo Buonerba, Matteo Ferro, Livio Puglia, Tania Policastro, Pasquale Rescigno, Piera Federico, Giovannella Palmieri, Luca Vaccaro, Davide Bosso, Antonella Virtuoso, Michela Izzo
Aim: This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel. Patients & methods: Patients were enrolled from March 2011 to December 2011 in an international expanded access
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69eb49620200106d9bd4b38a0eba3a8
http://hdl.handle.net/11588/569137
http://hdl.handle.net/11588/569137
Autor:
Giuseppe, Di Lorenzo, Carlo, Buonerba, Piera, Federico, Sisto, Perdonà, Michele, Aieta, Pasquale, Rescigno, Carmine, D'Aniello, Livio, Puglia, Antonella, Petremolo, Matteo, Ferro, Alfredo, Marinelli, Giovannella, Palmieri, Guru, Sonpavde, Vincenzo, Mirone, Sabino, De Placido
What's known on the subject? and What does the study add? Metastatic or locally advanced squamous cell carcinoma of the penis (SCCP) is generally incurable, but it can be palliated with systemic chemotherapy. Two retrospective studies, involving10 pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::2c8918be90c78d1aa219068249ba26ce
http://hdl.handle.net/11588/569152
http://hdl.handle.net/11588/569152